- Trials with a EudraCT protocol (144)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
144 result(s) found for: ST depression.
Displaying page 7 of 8.
EudraCT Number: 2010-023083-40 | Sponsor Protocol Number: SPON830-10 | Start Date*: 2012-03-19 |
Sponsor Name:Cardiff University | ||
Full Title: A Phase II study of neoadjuvant chemotherapy given before SCPRT as treatment for patients with MRI-staged operable rectal cancer at high risk of metastatic relapse | ||
Medical condition: Rectal adenocarcinoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2016-004354-15 | Sponsor Protocol Number: DANPAPP | Start Date*: 2017-12-13 | ||||||||||||||||
Sponsor Name: Rigshospitalet | ||||||||||||||||||
Full Title: Prevalence, pattern and disease course of arthritis and enthesitis in patients with psoriasis, and the effect of apremilast in subclinical US-defined psoriatic arthritis - A population-based study ... | ||||||||||||||||||
Medical condition: Psoriasis and psoriatic arthritis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-002699-42 | Sponsor Protocol Number: DANBLOCK | Start Date*: 2018-09-28 | |||||||||||
Sponsor Name:Bispebjerg Frederiksberg Hospital | |||||||||||||
Full Title: Danish trial of beta blocker treatment after myocardial infarction without reduced ejection fraction (DANBLOCK) | |||||||||||||
Medical condition: Myocardial infarction. We wish to test whether long-term treatment with betablocker (bisoprolol, carvedilol, metoprolol or nebivolol) leads to better prognosis than no treatment in patients sufferi... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011144-19 | Sponsor Protocol Number: 12962A | Start Date*: 2009-11-19 | |||||||||||
Sponsor Name:LUNDBECK ITALIA | |||||||||||||
Full Title: A randomised, double-blind, placebo-controlled study to evaluate if rasagiline can improve depressive symptoms and cognitive function in non-demented, idiopathic Parkinson s disease patients. | |||||||||||||
Medical condition: Subjects will be recruited from the Movement Disorders Outpatient Clinics from academic and hospital institutions in Italy. Only subjects with a BDI-IA score > or = 15 at baseline will be enrolled.... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005534-20 | Sponsor Protocol Number: 05102006 | Start Date*: 2008-01-24 | |||||||||||
Sponsor Name:Imperial College London | |||||||||||||
Full Title: Effect of Erdosteine on inflammatory and oxidative biomarkers in sputum and exhaled breath in patients with COPD | |||||||||||||
Medical condition: Chronic obstructive pulmonary disease (COPD) of different severity | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002213-19 | Sponsor Protocol Number: ELICE-BD-O1 | Start Date*: 2019-09-19 | |||||||||||
Sponsor Name:University of British Columbia | |||||||||||||
Full Title: A 6-Week Randomised, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy of Lurasidone Adjunctive Therapy in Improving Cognitive Functioning in Euthymic Bipolar Disorder Pa... | |||||||||||||
Medical condition: Euthymic Bipolar disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002205-22 | Sponsor Protocol Number: SSAT047 | Start Date*: 2012-10-02 |
Sponsor Name:St Stephen's AIDS Trust | ||
Full Title: A phase III, open-label, multi centre pilot study to assess the feasibility of switching, individuals receiving Atripla or Kivexa plus Efavarinz with continuing Central Nervous System (CNS) toxicit... | ||
Medical condition: HIV | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-003187-20 | Sponsor Protocol Number: | Start Date*: 2015-05-21 |
Sponsor Name:Barts Health NHS Trust | ||
Full Title: A multicentre double-blind randomised controlled trial to assess the clinical- and cost-effectiveness of facet-joint injections in selected patients with non-specific low back pain: a feasibility s... | ||
Medical condition: Non-specific low back pain of more than three months' duration | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2007-005377-63 | Sponsor Protocol Number: 2-39-00240-134 | Start Date*: 2008-02-26 | |||||||||||
Sponsor Name:Beaufour Ipsen pharma | |||||||||||||
Full Title: Effect of oral EGb 761® on Brain Glucose Metabolism in Three Groups of Elderly with Memory Complaint, mild Alzheimer's Disease, and Cognitively Normal Elderly. Phase II, randomised, double-blind, ... | |||||||||||||
Medical condition: patients with either spontaneous memory complaint with ou without cognitive impairment or with newly diagnosed mild Alzheimer’s disease. | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004899-19 | Sponsor Protocol Number: UC-BCG-1911 | Start Date*: 2020-06-09 |
Sponsor Name:UNICANCER | ||
Full Title: Adjuvant PalbOciclib + LetrOzole combination for hormone receptor positive / HER2-negative, Intermediate Risk breast cancer | ||
Medical condition: Hormone receptor (HR) positive / HER2-negative localized breast cancer in menopausal patient considered as having an intermediate risk of relapse. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-001104-37 | Sponsor Protocol Number: ME/2011/3709 | Start Date*: 2014-10-06 | ||||||||||||||||
Sponsor Name:University Hospitals Bristol NHS Foundation Trust | ||||||||||||||||||
Full Title: Pulsed glucocorticoid replacement therapy for patients with adrenocortical insufficiency secondary to Addison’s disease and congenital adrenal hyperplasia | ||||||||||||||||||
Medical condition: Addison's disease and Congenital Adrenal Hyperplasia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-002470-32 | Sponsor Protocol Number: APHP190131 | Start Date*: 2021-09-30 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS ( AP-HP) | |||||||||||||
Full Title: NEw Clinical End-points in patients with primary Sjögren’s Syndrome (pSS): an Interventional Trial based on stratifYing patients | |||||||||||||
Medical condition: Primary Sjögren’s syndrome (pSS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) NL (Trial now transitioned) GR (Trial now transitioned) NO (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003220-21 | Sponsor Protocol Number: GA19/105668 | Start Date*: 2020-02-26 | |||||||||||||||||||||
Sponsor Name:University of Leeds | |||||||||||||||||||||||
Full Title: Management of diarrhoea in ulcerative colitis: multi-arm multi-stage trial of low FODMAP diet, amitriptyline, ondansetron, or loperamide: MODULATE. | |||||||||||||||||||||||
Medical condition: Diarrhoea in patients with stable ulcerative colitis. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003413-18 | Sponsor Protocol Number: IM101 | Start Date*: 2014-05-13 | |||||||||||
Sponsor Name:King’s College London [...] | |||||||||||||
Full Title: Arthritis Prevention In the Pre-clinical Phase of RA with Abatacept. | |||||||||||||
Medical condition: The target population for therapeutic intervention will be subjects who carry serum autoantibodies (antibodies to citrullinated protein antigens – ACPA; rheumatoid factor – RF) and who have joint p... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002719-87 | Sponsor Protocol Number: KPL-914-C002 | Start Date*: 2019-05-02 | |||||||||||
Sponsor Name:Kiniksa Pharmaceuticals, Ltd | |||||||||||||
Full Title: Phase 3, double-blind, placebo-controlled, randomized withdrawal study with open-label extension, to assess the efficacy and safety of Rilonacept treatment in subjects with recurrent pericarditis –... | |||||||||||||
Medical condition: Recurrent pericarditis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-024557-36 | Sponsor Protocol Number: VHCRP1007 | Start Date*: 2012-05-29 | |||||||||||
Sponsor Name:The Kirby Institute | |||||||||||||
Full Title: A phase IV open-label multicentre, international trial of response guided treatment with directly observed pegylated interferon alfa 2b and self-administered ribavirin for patients with chronic HCV... | |||||||||||||
Medical condition: Chronic Hepatitis C genotype 2 and 3 infection. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-002326-27 | Sponsor Protocol Number: COG0201 | Start Date*: 2022-09-14 | |||||||||||
Sponsor Name:Cognition Therapeutics, Inc. | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CT1812 IN SUBJECTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE | |||||||||||||
Medical condition: Mild to Moderate Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) ES (Completed) CZ (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005263-16 | Sponsor Protocol Number: NSC15001 | Start Date*: 2016-07-11 | ||||||||||||||||
Sponsor Name:Pharmatrophix Inc | ||||||||||||||||||
Full Title: A 6-months prospective, multi-center, double-blind, placebo-controlled, randomized, adaptive-trial-design study to evaluate safety, tolerability and exploratory endpoints of either placebo or two d... | ||||||||||||||||||
Medical condition: Mild to moderate Alzheimer's disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: AT (Completed) CZ (Completed) DE (Completed) SE (Completed) ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-003935-56 | Sponsor Protocol Number: TMC-CAN-05-03 | Start Date*: 2006-11-24 | |||||||||||
Sponsor Name:The Medicines Company | |||||||||||||
Full Title: A clinical trial comparing treatment with cangrelor (in combination with usual care) to usual care, in subjects who require percutaneous coronary intervention | |||||||||||||
Medical condition: Subjects with coronary atherosclerosis (excluding ST segment-elevation MI [STEMI]) who require PCI (with or without stent). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) ES (Completed) CZ (Prematurely Ended) LT (Completed) SK (Completed) DE (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002179-91 | Sponsor Protocol Number: MLE4901-101 | Start Date*: 2017-01-17 | |||||||||||
Sponsor Name:Millendo Therapeutics, Inc. | |||||||||||||
Full Title: A Double-blind, Randomized, Parallel-group, Placebo-controlled Study of MLE4901 for the Treatment of Polycystic Ovary Syndrome (PCOS) | |||||||||||||
Medical condition: Polycystic Ovary Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
